⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

July 15, 2024Open Access

Supplementary Figure S1 from Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer

Aditya Bardia Sheng Sun Nayana Thimmiah James T. Coates Bogang Wu Rachel O. Abelman Laura M. Spring Beverly Moy Phoebe Ryan Mark N. Melkonyan Ann H. Partridge Dejan Juric Jeffrey Peppercorn Heather A. Parsons Seth A. Wander Victoria Attaya Brenda Lormil Maria Shellock Aiko Nagayama Veerle Bossuyt Steven J. Isakoff Sara M. Tolaney Leif W. Ellisen

View Full Paper

Ask AI

Bookmark

Share

Abstract

Figure S1. Schematic illustrating proposed temporal window created by SG-mediated drug delivery to enable sequential TOP1i/PARP1i dosing

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Bardia et al. (2024) studied this question.

synapsesocial.com/papers/68e60477b6db643587598478 https://doi.org/10.1158/1078-0432.26302824

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S1 from Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer2024 · 1 citations
2Supplementary Figure S4 from Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer2024
3Supplementary Figure S4 from Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer2024
4Data from Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer2024
5Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast CancerOriginal Research · 2021 · 255 citations

Sequential combination of sacituzumab govitecan and talazoparib in metastatic triple negative breast cancer (mTNBC): Results from a phase II study.2024
Sequential Use of Trastuzumab Deruxtecan and Sacituzumab Govitecan in Patients with Breast Cancer: A Pharmacological Approach to Support the Clinical Rationale2026
Inhibitors of IAP/XIAP enhance activity of sacituzumab govitecan2026